Back to Search
Start Over
Immunogenicity and Reactogenicity Following 2- and 3-Dose SARS-CoV-2 Vaccination in Persons With HIV.
- Source :
-
Journal of acquired immune deficiency syndromes (1999) [J Acquir Immune Defic Syndr] 2023 Jan 01; Vol. 92 (1), pp. e3-e6. - Publication Year :
- 2023
-
Abstract
- Competing Interests: D.L.S. has the following financial disclosures: consulting and speaking honoraria from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallinckrodt, Thermo Fisher Scientific, Regeneron, and AstraZeneca. C.M.D. has the following financial disclosures: research grants from GlaxoSmithKline and Abbvie and served on a grant review committee for Gilead Sciences. A.H.K. has received consulting fees from Roche. The remaining authors have no funding or conflicts of interest to disclose.
Details
- Language :
- English
- ISSN :
- 1944-7884
- Volume :
- 92
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of acquired immune deficiency syndromes (1999)
- Publication Type :
- Academic Journal
- Accession number :
- 36476571
- Full Text :
- https://doi.org/10.1097/QAI.0000000000003112